BMS-232632 is a potent protease inhibitor with the potential for a once-daily dose, which may improve compliance in patients with HIV. This was the finding of preliminary results from phase II trials presented by Dr Ian Sanne (director, department of clinical microbiology and infectious disease, University of Witwatersrand, Johannesburg, South Africa) at a Bristol-Myers Squibb press conference on February 9. Data suggested that the efficacy of BMS-232632 was equivalent to that of nelfinavir, he said. Unconjugated hyperbilirubinaemia was the most common laboratory abnormality found and was experienced by 51 per cent of patients taking the drug. This had been managed by reducing the dose of the drug. Dr Sanne commented that BMS-232632 was not an enzyme inhibitor and was unlikely to interfere with anti-tubercular therapy.
Protease inhibitors had increased treatment options and life expectancy in patients with HIV, Dr Sanne said. In addition, these drugs had improved quality of life for patients - even those with advanced disease. However, non-compliance was causing resistance. He said: "The number of pills being taken by HIV patients today to help manage the virus is extraordinary and many of our patients' entire lives are centred around their pill regimens." Anything that made it easier for patients to take their medicine would be an advantage.

Many patients' lives revolve around complying with their medicines, Dr Sanne said